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ABSTRACT 
OBJECTIVE: The aim of the study was to evaluate whether a repeated exercise challenge 
test requires reconsideration of the final exercise-induced bronchoconstriction diagnosis due 
to a difference in test results, and if so, whether the difference is associated with exercise 
intensity.   
 
METHOD: A total of 20 referred subjects with symptoms strongly suggesting exercise-
induced bronchoconstriction performed two exercise challenge tests on a treadmill. The 
exercise protocol of the repeated test was adjusted. Forced expiratory volume in 1 second was 
measured before and at 1, 3, 6, 10, and 15 minutes after exercise. Ventilation and heart rate 
were measured during exercise.  
 
RESULTS: The exercise intensity was not significantly different between the two tests, yet 
five subjects tested positive in both tests. Ten subjects tested negative in both tests. Three 
subjects tested positive in the first test only, while two subjects tested positive in the second 
test only.  
CONCLUSION: Our study showed a 25% divergence in the diagnostic results of two 
consecutive exercise challenge tests on subjects with symptoms strongly suggesting exercise-
induced bronchoconstriction. The difference in the test results was not explained by a 
difference in the exercise intensity.  
 
Keywords: exercise challenge test, exercise-induced bronchoconstriction, forced expiratory 
volume in one second 
 
 
 
  
5 
 
SAMMENDRAG 
MÅLSETTING: Hensikten med studien var å evaluere om en repetert anstrengelsestest 
krever en revurdering av den endelige diagnosen anstrengelsesutløst bronkokonstriksjon på 
grunn av en forskjell i testresultater, og i så fall, hvorvidt forskjellen er relatert til 
anstrengelsesintensitet. 
METODE: Totalt tyve henviste subjekter med symptomer som tydet sterkt på 
anstrengelsesutløst bronkokonstriksjon gjennomførte to anstrengelsestester på tredemølle. 
Anstrengelsesprotokollen for den repeterte testen ble justert. Forsert ekspiratorisk volum på 1 
sekund ble målt før og 1, 3, 6, 10 og 15 minutter etter anstrengelse. Ventilasjon og hjerterate 
ble målt under anstrengelse.  
RESULTATER: Anstrengelsesintensiteten var ikke signifikant forskjellig mellom de to 
testene. Likevel var det fem subjekter som testet positivt på begge testene. Ti subjekter som 
testet negativt på begge testene. Tre subjekter som testet positivt kun første gang, mens det 
var to subjekter som testet positivt kun andre gang.  
KONKLUSJON: Vår studie viste 25 % avvik i de diagnostiske resultatene av to 
etterfølgende anstrengelsestester på subjekter med symptomer som tydet sterkt på 
anstrengelsesutløst bronkokonstriksjon. Forskjellen i testresultatene kunne ikke forklares av 
en forskjell i anstrengelsesintensiteten.  
 
Nøkkelord: anstrengelsestest, anstrengelsesutløst bronkokonstriksjon, forsert ekspiratorisk 
volum i ett sekund  
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ABBREVIATIONS 
ATS = American Thoracic Society 
BF = breathing frequency 
BR = breathing reserve 
DL,CO = pulmonary diffusing capacity for carbon monoxide 
ECT = exercise challenge test 
EIB = exercise-induced bronchoconstriction 
ERS = European Respiratory Society 
FENO = fractional exhaled nitric oxide 
FEV1 = forced expiratory volume in one second 
FVC = forced vital capacity 
HR = heart rate 
MVV = maximum voluntary ventilation 
RER = respiratory exchange ratio 
RV = residual volume (volume of gas remaining in the lungs after maximal exhalation) 
TLC = total lung capacity (volume of gas in the lungs after maximal inspiration, or the sum of 
all lung volume compartments) 
VE = ventilation 
VO2 = oxygen uptake 
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INTRODUCTION 
Exercise-induced bronchoconstriction (EIB) is related to increased ventilation (VE) during 
exercise and describes the transient airway narrowing following exercise (Spooner, Saunders, 
& Rowe, 2002). Usually, maximum bronchoconstriction occurs 3–15 minutes after exercise 
(Brudno, Wagner, & Rupp, 1994) and subsides spontaneously within 20–60 minutes (Rupp, 
1996). The symptoms of EIB may include coughing, wheezing, shortness of breath, premature 
fatigue, and chest tightness (Spooner et al., 2002; Spooner, Spooner, & Rowe, 2003). As EIB 
often is the first sign of asthma (Ernst, Ghezzo, & Becklake, 2002) a reliable diagnosis and 
optimal treatment are important for affected people’s physical performances and self-esteem. 
PREVALENCE OF EXERCISE-INDUCED BRONCHOCONSTRICTION 
EIB is reported in most asthmatic patients, and is also more frequent in atopic (allergic) 
individuals (Rupp, 1996). However, EIB can also occur in individuals without signs of 
clinical asthma or atopy, such as elite athletes (Rundell & Slee, 2008). The true prevalence of 
EIB in the general population is poorly defined (Rupp, 1996), and the reported prevalence in 
the literature varies due to discrepancy in methods used for diagnosis, e.g. self-reported 
symptoms versus objective lung-function measurements (Rundell et al., 2001). Nevertheless, 
Rupp (1996) reported the prevalence of EIB in the general population to be 12–15% and other 
studies suggest a prevalence rate between 26% and 50% among specific athletes (Mannix, 
Farber, Palange, Galassetti, & Manfredi, 1996; Rundell et al., 2001; Wilber et al., 2000). EIB 
may be most frequent in children and young adults (McFadden & Gilbert, 1994) and it is 
reported more prevalent in female Olympic winter sport athletes than their male counterparts 
(Wilber et al., 2000). However, in the absence of valid studies the true prevalence is 
uncertain. 
EXERCISE CHALLENGE TEST 
Symptoms alone are not sensitive nor specific predictors of EIB (Rundell et al., 2001). In 
order to diagnose the presence of EIB, reported symptoms can be evaluated using different 
provocation tests. A standardized exercise challenge test (ECT) on a treadmill is commonly 
performed, whereby a possible impairment of pulmonary function is measured by spirometry. 
The response to exercise is assessed as the post-exercise reduction in forced expiratory 
volume in one second (FEV1) expressed as a percentage of the pre-exercise value. The 
European Respiratory Society (ERS) and American Thoracic Society (ATS) 
12 
 
recommendations both set a 10% reduction in FEV1 as a criterion for EIB (Crapo et al., 2000; 
Sterk et al., 1993).  
Intensity of the exercise challenge test 
Exercise intensity influences the sensitivity of an ECT because a major factor determining the 
severity of EIB is the pulmonary VE reached and sustained during exercise. An ECT can be 
sensitive and specific if exercise minute ventilation is standardized (Weiler et al., 2007). 
Therefore, ATS guidelines state that VE during an ECT should reach 40–60% of the predicted 
maximum voluntary ventilation (MVV), estimated as FEV1×35, for a period of 4 minutes 
with total test duration of 6–8 minutes. Correspondingly, the guidelines recommend an 
exercise intensity of 80–90% of heart rate maximum (HRmax), estimated by the formula: 
HRmax = 220 − age, for a period of 4 minutes (Crapo et al., 2000). However, as there is high 
individual variance in HRmax (Tanaka, Monahan, & Seals, 2001) it has been reported that 
heart rate based ATS standard protocols may not ensure sufficient exercise intensity to induce 
bronchoconstriction (Trümper, Mäueler, Vobejda, & Zimmermann, 2009). Moreover, a study 
by Carlsen, et al. (2000) has demonstrated a significant increased reduction in lung function 
after an ECT performed at 95% of estimated HRmax compared to an intensity of 85% of 
estimated HRmax. Thus, adequate intensity of an ECT may be essential to achieve a reliable 
diagnosis of EIB. 
Repeated exercise challenge test 
The impact of a repeated ECT in a clinical setting is not well established. However, the 
reproducibility of an ECT has been investigated. Dahlén et al. (2001) demonstrated the 
reproducibility of maximum per cent reduction in FEV1 as an outcome measurement after a 
standardized ECT to be 72%, hence the inter-subject variability accounted for 28% of the total 
variance. Furthermore, a recent study identified agreement of 76% in test results between two 
ECTs when examining subjects without a definite diagnosis of asthma. The results 
demonstrated variability in the presence and severity of EIB, despite standardization of 
intensity, duration, and condition of the inspired air, and also suggest that more than one ECT 
may be required to exclude or diagnose EIB (Anderson et al., 2010).  
The HR formula recommended by the ATS is usually applied (Carlsen et al., 2008). Trümper 
et al. (2009) suggested in the previously mentioned study that individual HRmax should be 
achieved before conducting an ECT in order to ensure adequate intensity of the test. In 
addition, a potential learning effect from foregoing practise tests has been reported in e.g. 
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COPD (chronic obstructive pulmonary disease) patients (ATS, 2003; Salzman, 2009; 
Swinburn, Wakefield, & Jones, 1985). Therefore, conducting a repeated ECT, based on the 
knowledge of the first test, introduces the possibility to adjust the exercise protocol on an 
individual basis and may also result in the subject tested becoming accustomed to the testing 
procedure. Thus, we hypothesized greater intensities of the repeated ECTs, and consequently 
a greater number of positive repeated ECT results. Also, because of the reported variability in 
repeated ECT results, an additional test may be useful. To our knowledge, no prior studies 
have examined the impact of a repeated ECT in which the exercise protocol can be adjusted. 
Thus, in our opinion the usefulness of performing a repeated ECT, as opposed to one test to 
achieve more reliable results in general, needs to be more extensively investigated.  
The aim of the study was to evaluate whether a repeated ECT requires reconsideration of the 
final EIB diagnosis due to a difference in test results, and if so, whether the difference is 
associated with exercise intensity. 
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MATERIAL AND METHODS 
STUDY DESIGN 
We conducted a test-retest evaluation study in a clinical setting. The evaluation was designed 
to compare the number of positive ECTs versus negative ECTs performed on two different 
occasions, and to assess a possible association between the test results and exercise intensity. 
Recruitment and testing took place at the Clinic for Allergies and Airway Diseases (Klinikk 
for allergi og luftveissykdommer, KAL) in Oslo.  
SUBJECTS 
Two pulmonologists recruited males and females during consultations following routine 
testing at KAL. The subjects, all of whom were volunteers, were enrolled if they were aged 
between 16 years and 45 years and had been referred to KAL by their general practitioners. At 
least three out of five questions relating to symptoms strongly suggesting EIB (coughing, 
wheezing, shortness of breath, lack of physical performance, and chest tightness) had to be 
confirmed by the subject in order for them to be included in the study (Appendix 1: Inclusion 
form). This was to increase the positive predictive value of the ECTs. Subjects who had 
formerly been diagnosed with and treated for asthma and who still fulfilled the inclusion 
criteria were also included in the study. Written informed consent was obtained from each 
subject (Appendix 2: Informed consent). 
Exclusion criteria were evaluated by the responsible pulmonologist and involved the lack of 
ability to perform an ECT with maximum effort, clearly abnormal electrocardiography 
(ECG), uncontrolled hypertension, or any known pulmonary diseases other than asthma. 
A total of 20 subjects, 12 females and 8 males, between 18 and 39 years of age were included. 
All subjects were Norwegian with the exception of one who was African. Three subjects 
participated in competitive sports. Eleven subjects undertook regular physical activity in their 
leisure time, and six subjects rarely or never undertook physical activity. Three subjects had 
not used a treadmill before. One subject had performed an ECT at the age of 8 years, and two 
subjects had completed a laboratory assignment which involved performing an ECT. Ten 
subjects used asthma medication, ten subjects did not use any asthma medication and two 
subjects used antihistamines.  
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CONDITIONS BEFORE TESTS 
All subjects reported feeling well on the days when the tests were performed and also in the 
three preceding days (no sick leave from school or work). Subjects with an ongoing 
respiratory tract infection or recent respiratory infection evaluated by the responsible 
pulmonologist had their designated day of testing postponed. No exercise was undertaken 
(prior to the ECT) on the days of testing. This was because of the possibility of developing 
refractoriness, whereby repeated exercise under identical conditions induces less than 50% of 
the initial asthmatic response (Lee & Anderson, 1985). Anti-asthmatic medication and 
antihistamines were withheld in accordance with ERS guidelines (Roca et al., 1997). Inhaled 
short-acting β2-agonists were withheld for 8 hours prior to testing, inhaled long-acting β2-
agonists for the last 72 hours, inhaled steroids on the test days and antihistamines for the last 7 
days. 
PROCEDURES 
Subjects were recruited between August 2010 and February 2011, and concurrent testing 
started in September 2010 and was completed in March 2011. The subjects visited KAL three 
times: on the inclusion day and on the two test days. There were between 1 and 90 (mean 24) 
days between the inclusion day and test day 1. After inclusion, the ECTs were performed on 
consecutive visits. The subjects completed the repeated ECT between 7 and 28 (mean 14) 
days after the first ECT. To minimize inter-observer variation, the same test technician (the 
researcher) performed the measurements on test day 1 and test day 2.   
 
Inclusion day: 
The routine testing consisted of anthropometric data registration, assessment of medication, 
allergy skin prick testing, lung function measurements including reversibility following 
inhalation of Salbutamol (asthma medicine), fractional exhaled nitric oxide (FENO) 
measurements, static lung volume measurements (RV, residual volume and TLC, total lung 
capacity), and pulmonary diffusing capacity for carbon monoxide measurements (DL,CO). 
Elevated FENO may indicate airway inflammation, and static lung volume measurements and 
diffusing capacity measurements may exclude other pulmonary diseases than asthma. 
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Test day 1:  
The procedure on test day 1 included resting blood pressure measurement, resting ECG 
recording, MVV measurements, an ECT, and treatment (Salbutamol). 
Test day 2: 
The procedure on test day 2 was identical to that on test day 1, except for the exclusion of 
resting blood pressure measurement and resting ECG recording. In addition, the exercise 
protocol of ECT 2 was adjusted by the test technician in collaboration with the test subject, 
based on ECT 1. If the subject ran for less than 8 minutes in ECT 1, an increased running time 
was encouraged in ECT 2. If subject was not completely exhausted after 8 minutes in ECT 1, 
speed and/or elevation of ECT 2 was increased if feasible. If the subject reported that the 
mask was the reason for terminating ECT 1, he or she was informed of the possibility of 
taking it off and continuing to run rather than terminating ECT 2. If the subject reported stiff 
legs as the reason for terminating ECT 1, speed and/or elevation of ECT 2 was adjusted.  
OUTCOMES 
The primary outcomes were maximum reduction in FEV1 from before to after ECT 1 and 
ECT 2 (% pre-exercise), and exercise intensity measurements (VE and HR) in ECT 1 and 
ECT 2. In addition, oxygen uptake (VO2), breathing frequency (BF), respiratory exchange 
ratio (RER), and breathing reserve (BR) were measured. 
MEASUREMENTS 
Anthropometric data 
Anthropometric data (age, sex, height, and weight) were recorded as a basis for determining 
individual predicted values and to express oxygen uptake related to bodyweight. Height (to 
the nearest centimetre) and weight (to the nearest kilogram) were measured while the test 
subjects were clothed, but without shoes.  
Skin prick test  
Skin prick tests were performed in accordance with published guidelines (Dreborg, 2005) 
with the following allergens: horse dander, dog dander, cat dander, rabbit dander, birch 
pollen, grass pollen (Timothy), mug worth pollen, Alternia tenuis, Cladosporium herbarum, 
house dust mites (Dermatophagoides pteronyssinus), and latex (Soluprick, ALK, 
Copenhagen, Denmark and Allergopharma, Hamburg, Germany).  
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The criterion for being considered allergic to an allergen was a wheal size > 3 mm (Sporik, 
Hendersom, & Hourihane, 2009). 
Fractional exhaled nitric oxide 
FENO was measured using an analyser (DENOX 88, ECO MEDICS AG, Dürnten, 
Switzerland) according to published guidelines (ATS & ERS, 2005). FENO is given in parts per 
billion (ppb). According to the manufacturer; FENO > 30ppb may indicate airway 
inflammation. 
Lung function with reversibility 
Lung function with reversibility was measured by a spirometer (Flowhandy ZAN 100 USB, 
nSpire Health GmbH, Oberthulba, Germany) according to published guidelines (Miller et al., 
2005). FEV1 in litres and in % of predicted and the ratio FEV1/FVC (forced vital capacity) are 
given. Reversibility was assessed following inhalation of Salbutamol (0.4 mg from a 
pressurized metered dose inhaler). An increase in FEV1 of ≥ 12% and ≥ 200 ml above 
baseline was taken as a positive response to Salbutamol. We used accepted reference values 
and ethnicity was taken into account, i.e. a correction factor was applied to adjust European 
reference values for application to Africans (Quanjer et al., 1993).  
Static lung volumes 
Static lung volumes were measured using bodyplethysmography (ZAN 500 Body USB, 
nSpire Health GmbH, Oberthulba, Germany), according to published guidelines (Wanger et 
al., 2005). Among the subdivisions of static lung volumes, RV and TLC were recorded. We 
used accepted reference values as mentioned above (Quanjer et al., 1993).  
Pulmonary diffusing capacity for carbon monoxide 
DL,CO was measured using a CO/CH4 (methane) analyser (ZAN 300 MGA USB, nSpire 
Health GmbH, Oberthulba, Germany), according to published guidelines (Cotes, Chinn, 
Quanjer, Roca, & Yernault, 1993). We used accepted reference values as mentioned above 
(Cotes et al., 1993).  
Blood pressure 
For safety reasons, resting blood pressure was measured prior to exercise by the use of an 
automated blood pressure device (M3 Intellisense HEM-7051-E, OMRON HEALTHCARE, 
Kyoto, Japan). We measured blood pressure once.  
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Electrocardiography 
Resting 12-lead ECG was measured for safety reasons prior to exercise by the use of an ECG 
recorder (AR 1200 ADV, Cardiette, Cavareno, Italy). Prior to the ECT, interpretation of the 
electrocardiogram was performed by the pulmonologist responsible.  
Lung function before and after exercise 
Lung function was measured using a spirometer (Flowhandy ZAN 100 USB, nSpire Health 
GmbH, Oberthulba, Germany) according to published guidelines (Miller et al., 2005). FEV1 
and FVC were measured before and 1, 3, 6, 10, and 15 minutes after exercise and 10 minutes 
after inhalation of Salbutamol (0.4 mg). Full FVC manoeuvres were not requested after 
exercise because this might have tired the subjects (Weiler et al., 2007). Salbutamol was 
included to reverse possible bronchoconstriction. We used accepted reference values, as 
mentioned above (Quanjer et al., 1993). 
Maximum voluntary ventilation 
Before exercise, MVV was measured using an analyser (ZAN 600 USB, nSpire Health 
GmbH, Oberthulba, Germany) according to published guidelines (Miller et al., 2005). The 
value was multiplied by six which results in the MVV expressed in litres per minute (L min
-1
). 
This was measured to calculate BR after measuring VEpeak during the ECT 
(MVV − VEpeak = BR) and to calculate ventilation in percentage of MVV (VE % MVV) for 
the last 4 minutes of the ECTs.  
Exercise challenge test 
The ECTs were performed under laboratory conditions according to ERS guidelines (Roca et 
al., 1997). ECT 1; the temperature was between 18°C and 21°C, the relative humidity was 
between 20% and 46%, and the barometric pressure was between 97.7 kPa and 101.4 kPa. 
ECT 2; the temperature was between 19°C and 22°C, the relative humidity was between 19% 
and 45%, and the barometric pressure was between 96.1 kPa and 102.0 kPa. The mean 
outdoor temperature in Oslo 30 minutes before scheduled testing at KAL was −2 (SD 6) °C 
and −4 (SD 4) °C on test day one and two respectively. 
Exercise was performed by running on a motorized treadmill (h/p/cosmos quasar med 4.0, 
h/p/cosmos sports & medical gmbh, Nussdorf-Traunstein, Germany) for 6−8 minutes. The 
initial incline of the treadmill was 3%. The speed and incline were adjusted throughout the 
test with the aim of achieving a workload of ≥ 95% of estimated HRmax (220 − age) in the last 
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4 minutes of each test. Each subject’s VE and HR were monitored according to ATS and ERS 
guidelines, for both ECTs. The ventilation was > 40% of measured MVV and estimated MVV 
(FEV1×35) for each subject, during each of the last 4 minutes of the tests. Also, the HR 
was >80% of estimated HRmax for each subject during each of the last four minutes of the 
tests. In addition, the subjects assessed their own perception of effort and exhaustion 
immediately after completing the test by using the Borg CR 10 Scale for rating perceived 
exertion (Borg, 1998). The test could have been stopped at any time. Furthermore, the 
subjects were wearing a chest belt and a harness, attached by rope to the crossbar of the 
treadmill’s safety arch, and one pull on the rope would have activated the emergency stop.  
VE, VO2, BF, and RER were measured during exercise. Each subject wore a face mask 
attached to a flow sensor (ZAN VIP flow sensor, nSpire Health GmbH, Oberthulba, 
Germany) which was connected to an analyser (ZAN 600 USB, nSpire Health GmbH, 
Oberthulba, Germany). In order to determine the respiratory flow, gas concentrations were 
constantly sampled, and by using fast response selective analysers for O2 and CO2 the values 
were time aligned providing breath by breath measurements. Calibration was verified each 
test day. Heart rate was continuously recorded by use of a heart rate monitor (Polar WearLink 
W.I.N.D, Polar Electro Oy, Kempele, Finland).  
Maximum percentage reduction in FEV1 after exercise test was calculated by (pre-exercise 
FEV1 − minimum post exercise FEV1)/(pre-exercise FEV1) x 100%. Minimum post-exercise 
FEV1 was the lowest recorded value at 1, 3, 6, 10, or 15 minutes after test, taking the better of 
two acceptable attempts at each time point. Values were rounded. A subject was deemed 
positive if there was a reduction of ≥ 10% in FEV1. A reduction of 10–20%, 20–40% 
and >40% was considered mild, moderate and severe respectively (Eggleston, 1984). The 
highest recorded VE, HR, VO2, BF, and RER values during exercise were determined as 
VEpeak,  HRpeak, VO2 peak, BFpeak and RERpeak. VO2 and VE were both measured in L min
-1
, BR 
in breath min
-1
 and HR in beats min
-1
. ZAN-Tech Software was used to interpret the results. 
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STATISTICAL ANALYSIS  
Subject characteristics are given individually and as mean values and standard deviations. The 
results are given as means with 95% confidence intervals. Paired t-tests were applied to assess 
differences in lung function between baseline and ECT 1 and between baseline and ECT 2. 
They were also used to assess differences in intensity and maximum reduction in FEV1 
between ECT 1 and ECT 2. P-values of < 0.05 were considered statistically significant. All 
statistical analyses were performed using PASW V.18.0 for Windows software (SPSS Inc, 
Chicago, Illinois, USA). To create the graph, we used the SAS 9.2 statistical package (SAS 
Institute Inc., Cary, North Carolina, USA). 
ETHICS 
The study was performed in accordance with the principles stated in the Declaration of 
Helsinki, and was approved by the Regional Committee for Medical Research Ethics, Health 
Region North, Norway (Appendix 3: Regional Committee approval). The study was also 
registered with ClinicalTrials.gov, registration number NCT01214551  
(Appendix 4: ClinicalTrials.gov-Protocol registration receipt). Patient data are kept 
confidential. 
Study participation was evaluated to involve minimal health risk and the measurements were 
taken in concordance with regular clinical practice. To ensure subjects’ safety, a medically 
responsible pulmonologist was available at all times during the testing, and a defibrillator was 
accessible in the laboratory exercise room. ECG registration and blood pressure measurement 
were included prior to the first ECT to increase safety level of maximal effort exercise tests. 
Safety garments ensured that subjects could not fall off the treadmill, thus preventing any risk 
of injury.  
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RESULTS  
BASELINE CHARACTERISTICS 
Table 1 shows a summary of the subjects’ characteristics at baseline. Blood pressure, ECG, 
static lung volumes, and diffusing capacities were normal for all subjects. There were no 
significant differences in the group’s lung function (FEV1 and FVC) between baseline and test 
day 1 or between baseline and test day 2 (data not shown).  
Table 1: Baseline characteristics of the subjects 
Notes: Body mass index (BMI); symptoms (1: cough, 2: wheeze, 3: shortness of breath, 4: lack of physical 
performance, and 5: chest tightness); exercise (h/w, hours of endurance training per average week); forced 
expiratory volume in 1 s (FEV1 in litres and in percentage of predicted); forced vital capacity (FVC); fractional 
exhaled nitric oxide (FENO in ppb parts per billion); 
a
 smoker, 
b
 snuff user, 
c
 African, 
d
 positive reversibility test, 
1,2,3 
medication (1: short-acting β2-agonists, 2: long-acting β2-agonists, 3: inhaled steroids); and m missing value.  
 
No  ♀,♂   Age 
years 
Height, weight, 
BMI 
cm, kg, kg/m
2 
Symptoms 
1,2,3,4,5 
Atopy 
Y, N 
Exercise 
h/w 
FEV1 
L 
FEV1 
% pred. 
FEV1/ 
FVC 
FENO 
ppb 
  1
1
      ♀         24 163   73   27   1,2,5 Y   .5 2.9   90 85 10 
  2
a,1,3   ♀ 27 163   48   18   1,2,5 N   .0 3.4 109 89   6 
  3
1,2
    ♀ 22 163   61   23   1,2,3,5 N 4.5 3.0    92 68 61 
  4
1,3
    ♀  39 171   66   23   3,4,5 N   .5 2.8   88 68 13 
  5       ♂ 36 188   71   20   1,2,3,4,5 Y 2.0 4.6 101 72 28 
  6
1,3
    ♀ 35 183   95   28   1,2,4,5 N 1.0 4.1 108 80   7 
  7       ♂ 27 179   73   23   1,2,3 N 5.0 3.7   84 72 73 
  8       ♀ 21 160   63   25   1,3,5 N 1.5 3.4 108 89 46 
  9       ♀ 20 166   62   23   1,3,5 N 2.0 3.0   90 86 22 
10
1
      ♀ 18 156   53   22   1,2,3,4,5 Y   .0 2.5   85 86 60 
11
1
      ♂ 23 189   89   25   1,2,3 Y 4.0 5.0 100 79 69 
12       ♀ 29 165   63   23   1,2,3,5 Y 1.0 3.3 103 82 65 
13
1,3
    ♀ 28 163   69   26   1,2,5 N   .0 3.1   97 79 m 
14       ♀ 24 167   69   25   1,2,3,5 Y   .0 3.5 104 88 m 
15
b
      ♂ 31 181   75   23   1,2,3,5 N   .0 4.8 109 70   5 
16       ♂ 29 194   84   22   1,3,4,5 Y 7.0 5.1 103 73 12 
17       ♂ 31 175   67   22   1,3,5 Y   .0 3.7   90 82 15 
18
1
      ♀ 27 168   72   26   1,2,3,5 Y 1.0 2.9   86 76 15 
19       ♂ 35 176   71   23   1,2,3,5 Y 2.0 4.2 103 81 14 
20
c,d,1,3♂ 26 164   65   24   2,3,5      Y   .0 1.6   46 67 55 
Mean 
(SD) 
Sum    12/8 
28 
(6) 
172   69   24 
(11) (11) (2) 
 
 
18/15/16/5/18 
 
 
11/9 
1.6  
(2.0) 
3.5 
(0.9) 
95 
(14) 
79 
(7) 
 
32 
(25) 
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COMPLIANCE AND ADVERSE EVENTS 
The compliance with both ECTs was 100%. Dizziness and nausea were reported by several 
subjects, but with spontaneous recovery. On test day 1, irregular HR was recorded in three 
subjects and one subject did not measure VO2 and RER due to equipment error. Also, one 
subject had a small face mask leakage, and one subject did not perform MVV due to having a 
headache. On test day 2, irregular HR was recorded in one subject. Also, two subjects were 
unable to complete the ECT wearing a face mask, due to the subjective feeling of not being 
able to breathe.  
EXERCISE INTENSITY 
On an individual base, exercise intensity measurements were similar for both tests. Also, the 
subjects’ perceptions of their own efforts and level of exertion were similar in ECT 1 and 
ECT 2, and they reported ≥ 9 on Borg CR 10 Scale on both tests. Moreover, when assessed at 
group level, there were no significant differences in exercise intensity measurements (Table 
2). Mean VE % MVV during the last 4 minutes of ECT 1 was 82% while for ECT 2 it was 
81%. Mean VE % estimated MVV was 79% on ECT 1 and 81% on ECT 2. Mean HR % 
predicted HRmax during the last four minutes was 94% on ECT 1 and 93% on ECT 2. Further, 
there were no significant differences in mean values of VEpeak, HRpeak, VO2peak, BFpeak, 
RERpeak or BR between the two ECTs. The durations of the tests were also similar. The mean 
duration of ECT 1 was 6 minutes 52 seconds and the mean duration of ECT 2 was 6 minutes 
49 seconds.  
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Table 2: Intensity of exercise challenge test 1 and exercise challenge test 2 for the 
subjects 
Variable ECT1 
Mean (SD) 
ECT2 
Mean (SD) 
Difference  
Mean (95% CI) 
 
P 
VE % MVV 82 (16) 81 (18) -2.7 (-7.4, 2.1) 0.25 
VE % estimated MVV   79 (8) 81 (12) -1.6 (-4.7, 1.5) 0.30 
HR % estimated HRmax   94 (4)   93 (4) -0.0 (-1.4, 1.3) 0.94 
VEpeak (L min
-1
)     112 (27)     118 (32) -0.5 (-3.8, 2.7) 0.74 
HRpeak (beats min
-1
) 186 (8) 184 (9) -0.2 (-1.8, 1.5) 0.81 
VO2 peak (ml kg
-1
 min
-1
)   44 (6)   46 (8)  0.6 (-0.7, 1.9) 0.36 
BFpeak (breath min
-1
)   56 (8)   56 (9) -0.5 (-2.9, 1.9) 0.65 
RERpeak 1.11 (0.05) 1.10 (0.05)         -0.013 (-0.033, 0.018) 0.21 
BR (L min
-1
)   8 (22) 15 (19) 8.9 (-2.4, 20.3) 0.12 
Ventilation (VE) % of maximal voluntary ventilation (MVV); VE % of estimated MVV and heart rate (HR) % of estimated 
HR maximum (HRmax) in the last 4 minutes (mean) of exercise challenge test (ECT) 1 and 2; Peak ventilation (VEpeak), peak 
heart rate (HRpeak), peak oxygen uptake (VO2 peak), peak breathing frequency (BFpeak), peak respiratory exchange ratio 
(RERpeak) and breathing reserve (BR) of the ECTs. Difference: negative values relate to greater intensity of ECT1. Mean 
ECT2 − mean ECT 1 ≠ mean difference due to missing values.  
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REPEATED EXERCISE CHALLENGE TEST 
The agreement in ECT results was 75% with 50% (10) negative and 25% (5) positive on both 
tests (Table 3). Five subjects had a positive test result on only one of the two tests, three on 
the first test, and two on the second test. Disregarding test results, the maximum reduction in 
FEV1 both increased and decreased from test 1 to test 2. 
Table 3: Maximum reduction in forced expiratory 
volume in 1 s (% pre-exercise) from before to after exercise 
challenge test 1 and 2, and the test results (positive/negative) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Subjects sorted according to test results 
 
  
Subject 
No 
ECT1 
Reduction (Result) 
ECT2 
Reduction (Result) 
  3 -65 (pos) -58 (pos) 
  6 -13 (pos) -33 (pos) 
  8 -15 (pos) -10 (pos) 
11 -18 (pos) -20 (pos) 
20
 
-34 (pos) -33 (pos) 
  2   -4 (neg)   -2 (neg) 
  4   -2 (neg)   -3 (neg) 
  5   -3 (neg)   -4 (neg) 
  9   -3 (neg)   -6 (neg) 
13   -2 (neg)   -2 (neg) 
14   -5 (neg)   -3 (neg) 
15   -9 (neg)    1 (neg) 
16   -4 (neg)    0 (neg) 
17    1 (neg)                    -4 (neg) 
19   -6 (neg)   -8 (neg) 
  1 -14 (pos)   -8 (neg) 
  7 -16 (pos)   -2 (neg) 
10 -13 (pos)   -9 (neg) 
12   -8 (neg) -10 (pos) 
18   -9 (neg) -13 (pos) 
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When assessed at group level, there was no significant difference in mean maximum 
reduction in FEV1 (% pre-exercise) between ECT 1 and ECT 2. The mean maximum 
reduction in FEV1 was 12% and 11% after ECT 1 and ECT 2 respectively. The mean 
difference was 1 percentage point (−2.5, 4.0), (p = 0.63), (N = 20). Furthermore, the mean 
reduction in FEV1 after 1, 3, 6, 10, and 15 minutes after exercise and 10 minutes after 
medication was not significantly different between ECT 1 and ECT 2 (Fig. 1). 
 
 
Figure 1: Forced expiratory volume in 1 s (FEV1) pre- (P) and 1, 3, 6, 10, and 15 minutes after exercise 
(exercise challenge test ECT 1 and ECT 2) and 10 minutes after medication (AM). Results are given as 
means with 95% confidence intervals. N = 20. 
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DISCUSSION 
There were no significant differences in the exercise intensity between the two tests. 
However, five out of twenty subjects had different diagnostic test results. Hence, the 
differences in test results may not be related to the exercise intensity and it follows that 
accustomization to the testing procedure of the repeated ECT was not demonstrated.  
In contrast to our hypothesis, the subjects seemed to achieve maximal performance already in 
the first ECT. Mean VE % measured and estimated MVV and mean HR % estimated HRmax 
in the last 4 minutes of the tests were higher than minimum recommendation levels in both 
tests. Furthermore, mean heart rate in % of estimated HRmax in the last 4 minutes of the tests 
was 94% and 93% in ECT 1 and ECT 2 respectively. This is close to 95%, which according to 
the study by Carlsen et al. (2000) may represent an adequate intensity level. The other 
intensity measurements (table 2) and the subjects’ perception of their own exertion may also 
indicate maximal exertion. Consequently we believe that adjustments to the repeated exercise 
protocols were not able to result in any significant intensity enhancements.  
Because we did not demonstrate any significant intensity differences, we were not surprised 
that we did not find a greater number of positive repeated test results. In fact, no trend was 
demonstrated in the five subjects with different test results: three subjects tested positive in 
the first test only, and two subjects tested positive on the second test only. Also, disregarding 
test results, the maximum reduction in FEV1 both increased and decreased from test 1 to test 2 
and thus did not demonstrate a trend either. Furthermore, the five subjects with different test 
results had only mild (10–20%) reductions in FEV1. This finding is in line with Anderson et 
al. (2010), who suggest that for some subjects with mild symptoms more than one test may be 
required. They could neither explain the variation in their test results by a difference in 
exercise intensity (standardized), and hypothesized that the variability could have been due to 
environmental or dietary factors or to the intrinsic reproducibility of the test itself.  
Subjects 3, 6, 8, 11, and 20 tested positive in both tests. Subjects 3 and 20 demonstrated 
severe (> 40%) and moderate (20–40%) reductions in FEV1 respectively leaving little doubt 
about diagnosis. Subject 6 demonstrated a great difference in maximum reduction in FEV1 
between test 1 and 2. We can only speculate why, but the subject experienced coughing fits 
on both days which may have influenced the lung function measurements. A total of 10 
subjects tested negative in both tests. Only subjects 15 and 19 had borderline results. 
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However, subject 15 demonstrated technical improvements during lung function 
measurements on test day 2.   
Subjects 1, 7, and 10 tested positive in the first ECT only. In the case of subject 1, the 
reduction in FEV1 from before to after exercise was only ≥ 10% after 15 minutes. Reduction 
in FEV1 is usually sustained over two time points. Because we did not measure FEV1 beyond 
15 minutes we do not know whether the reduction in FEV1 was sustained or could have been 
due to respiratory muscle fatigue (Rundell & Sue-Chu, 2010). Also, occasional late phase 
responses may have been left out (Spooner et al., 2003). Nevertheless, we did not operate with 
the criteria of sustained reduction over two time points to identify a positive test because one 
time point has been common practice (Roca et al., 1997). Subject 7 on the other hand 
measured a reduction in FEV1 from before exercise to 3, 6, and 10 minutes after exercise, but 
spontaneously recovered after 15 minutes. As maximum bronchoconstriction usually occurs 
3–15 minutes after exercise, the spontaneous recovery after 15 minutes is ambiguous.  
Subjects 12 and 18 tested positive in the second ECT only. In both tests both subjects felt 
discomfort while running with a face mask on. Subject 18 took the mask off during ECT 2, 
and ended up running for additional 2 minutes 45 seconds, which may have resulted in the 
sustained high ventilation required to elicit the EIB response.  
Subjects 1, 10, 12, and 18 had borderline results in both tests. We used a cut-off value of 10% 
reduction in FEV1 as criterion of a positive ECT. Interestingly, using a 15% cut-off value 
which also has been recommended (Eggleston, 1984; Haby, Peat, Mellis, Anderson, & 
Woolcock, 1995) left us with only one subject (7) with different test results.  
Elevated FENO has been reported in subjects with asthma (Kharnitonov et al., 1994). In our 
study, baseline FENO > 30 ppb was measured in four out of the five subjects who had two 
positive tests and in three out of the five subjects who had different test results. In addition, 
none of the subjects with two negative tests had FENO > 30 ppb (two missing values) at 
baseline. Thus, the FENO measurements might indicate a relation to the test results, which is 
interesting because baseline FENO has been suggested to predict airway obstruction following 
exercise (García-Río et al., 2006).  
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Ten subjects used asthma medication, but still complained of EIB symptoms. Four tested 
positive in both tests, three tested negative in both tests, and three had different test results. 
Further, five of the ten subjects used inhaled steroids. Two of these had two positive tests 
results, while the other three had two negative test results. It cannot be ruled out that the use 
of inhaled steroids decreased the likelihood of a positive test result in these subjects. (Crapo et 
al., 2000).  
The included subjects reported at least three EIB symptoms, yet 10 subjects tested negative in 
both ECTs. This finding is in line with those made by Rundell et al. (2001), who concluded 
that self-reported EIB symptoms may yield both false positive and false negative test results. 
Their study involved elite athletes, but their findings seem to agree with ours. Partly, the 
prevalence reported in the literature is based on self-reported symptoms (Voy, 1986; Weiler, 
Metzger, Donnely, Crowley, & Sharath, 1986). Further, reported prevalence may also be 
based on ECTs. However, lack of standardization and especially inadequate intensity may 
reduce the sensitivity of exercise challenge tests (Carlsen et al., 2000). Consequently, 
objective testing and standardized ECTs with adequate intensity are of importance both for 
diagnostic purposes, but also with regards to epidemiological studies.  
We included subjects covering a large age range, thus reflecting a physically active period of 
life. The subjects turned out to be somewhat physically active in their leisure time, but only 
three subjects participated in competitive sports. The subjects’ activity levels differed and this 
was reflected in their VO2 measurements (range 32–61, mean 45) ml kg
-1
min
-1
. Moreover, 
three subjects had some previous ECT experience, in contrast to three subjects who had never 
run on a treadmill before. Regardless, this was not reflected in the subjects’ ECT 
performances. Further, we included one African subject. Africans may have smaller lungs 
with lower values for, for example, FEV1 compared to Europeans (Quanjer et al., 1993).  
However, ethnicity differences do not interfere with our primary outcomes.  
The testing lasted from September to March and the number of days between ECT 1 and ECT 
2 differed between 7 days and 28 days. We avoided the pollen season, but we cannot exclude 
that variation in outdoor weather conditions may have influenced the test results. However, 
the mean difference in temperature between the two tests was only 2°C. Also, the ECTs were 
not performed on the same time of day which may have influenced the results as well (Vianna 
et al., 2002). 
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The same test technician gave thorough information about study participation, reminded the 
subjects on each test day, guided the subjects through all measurements on test day 1 and test 
day 2, and encouraged maximal effort on the treadmill. We believe this was strength of our 
study, as there was 100% compliance in the case of both ECTs, despite the fact that 
performing an ECT is mentally and physically demanding. Also, the study was conducted in a 
centre of expertise and involved specialists in pulmonary diseases. We wanted to conduct a 
study that reflected the challenges in an everyday clinical setting. Conversely, the study could 
not be repeated as a blind study and also psychological factors influencing the test technician 
(researcher) and the subjects tested cannot be excluded.  
Limitation of time made it unfeasible to achieve a sample size that would generate sufficient 
statistical power. Therefore, the results should be interpreted with care and the findings should 
not be generalized. However, the small sample size made it possible for us to study the 
participants individually.  
Knowledge about the usefulness of a repeated ECT may be of importance to patients, clinical 
practice, and research work. A reliable assessment of EIB is of great value as optimal choice 
of treatment can be enabled and adaptations relating to exercise and sports can be made. Also, 
for a drug to be regarded as beneficial, knowledge about variability in maximum reduction in 
FEV1 is crucial. Nevertheless, a repeated ECT may identify extra subjects with EIB who 
tested false negative the first time, as well as over diagnosing subjects with EIB the second 
time. A repeated ECT may require reconsideration of the final EIB diagnosis. However, 
different test results make the diagnostic decision difficult. Which test should be emphasized? 
In any case, our results may suggest that a repeated ECT does not improve ECT performance 
with regard to exercise intensity. 
In summary, our study showed a 25% divergence in the diagnostic results of two consecutive 
ECTs on subjects with symptoms strongly suggesting EIB. The difference in test results was 
not explained by a difference in exercise intensity. One objective of further research should be 
to develop a more precise exercise challenge test protocol with definite control parameters to 
provide a more reliable test. 
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Rekruttering til forskningsprosjektet EIB 
 
Pasienten er henvist til klinikken KAL. Pasienten har gjennomgått tester etter vanlig 
prosedyre, og rekrutteres ved konsultasjon dersom det kommer frem at pasienten har 
symptomer ved anstrengelse og legen mistenker EIB. Også pasienter som har fått 
astmadiagnose og behandling tidligere, men allikevel har symptomer på treningsindusert 
astma inkluderes i studien. 
Rekrutteringen vil skje på grunnlag av inklusjonskriteriene nedenunder. 3 av 5 kriterier må 
oppfylles.  
Pasienten må møte opp til to testdager innenfor perioden Sept 2010-Mai 2011. Maksimalt skal 
det være 4 uker mellom de to testdagene. (med et mål om 2 uker ± 1 uke). Pasienten betaler 
ikke for de to testdagene, kun reiseutgifter.  
 
 
 
Inklusjonskriterier: 
⁯ 1. Hoste under anstrengelse eller innen 5 min etter anstrengelse.  
 
⁯ 2. Pipelyder under anstrengelse eller innen 5 min etter anstrengelse 
 
⁯ 3. Påfallende tungpustenhet, spesielt ekspirasjonsvansker e.l. under 
anstrengelse eller innen 5 min etter anstrengelse (varighet ca 5 min eller mer) 
 
⁯ 4. Manglende bedring av form/pust til tross for intensivering av trening 
 
⁯ 5. Tetthets-/tranghetsfølelse i brystet under eller etter anstrengelse 
 
 
 
Pasientens navn:______________________Føds.dato:____________________ 
Lege:_______________________________Dato:________________________ 
APPENDIX 1: Inclusion form
 
  Anstrengelsesutløst astma 13.10.2010     VOKSNE 
Forespørsel om deltakelse i forskningsprosjektet: 
”Sammenligning av to tredemølletester (provokasjonstester) for vurdering av 
anstrengelsesutløst astma”. 
Bakgrunn og hensikt:
Vi henvender oss til deg for å be om ditt samtykke til deltakelse i dette forskningsprosjektet. 
Formålet med studien er å få økt kunnskap knyttet til diagnostisering av anstrengelsesutløst astma.  
Studien gjennomføres som et samarbeidsprosjekt mellom ”Klinikk for allergi og 
luftveissykdommer” (KAL), Oslo, og ”Norges teknisk- naturvitenskapelige universitet”, (NTNU), 
Trondheim. Denne forespørselen går til personer av begge kjønn i alderen 16 til 45 år som er henvist 
til KAL og hvor det er mistanke om anstrengelsesutløst astma. 
Prosjektets innhold:
For deg innebærer prosjektet at du kommer til klinikken (KAL) to adskilte testdager innenfor en 4 
ukers periode i tidsrommet september 2010 - mai 2011. På hver testdag utføres en tredemølletest 
(provokasjonstest for anstrengelsesutløst astma). Lungefunksjon måles før og etter testen. Løp på 
tredemølle vil foregå i 6-8 minutter hvor du skal bli maksimalt sliten. Underveis registreres 
oksygenopptak og puls. Testen kan gi astmasymptomer som for eksempel tetthet i brystet, 
tungpustethet, hoste og økt slimproduksjon. Alle vil derfor få en inhalasjon med astmamedisin etter 
testen som en del av undersøkelsen. 
Den første testdagen vil du bli bedt om å svare på et spørreskjema angående astma og luftveisplager. 
Det vil også bli målt blodtrykk og hjertets elektriske aktivitet vil bli registrert (hvile EKG). 
Ved begge testdagene vil det i tillegg til tredemøllestesten bli utført andre lungefunksjonsmålinger 
som foretas rutinemessig hos alle pasienter som er henvist for astma og/eller pustebesvær under 
anstrengelse: Maksimal frivillig ventilasjon måles for å beregne pustereserve etter at man har målt 
ventilasjon under tredemølletesten. Nivå av nitrogenoksid i utåndingsluft kan si noe om 
betennelsestilstanden i luftveiene på måletidspunktet. Lungevolum, luftveismotstand og 
diffusjonskapasitet benyttes som hjelpemiddel i diagnostisering og behandling av lungesykdom.  
Viktig: Dine forberedelser: 
Ved de to testdagene må du ikke være under påvirkning av luftveisutvidende medikamenter 
(bronkodilatorer) og du må ikke trene samme dag som du skal testes. 
Dette betyr at: 
Ventoline®, Salbuvent®, Inspiryl®, Bricanyl®, Airomir® ikke skal taes de siste 8 timer før testene. 
Serevent®, Seretide®, Oxis® og Symbicort® må ikke brukes de siste 3 døgn før testene. 
Singulair® skal ikke brukes de siste 3 døgn før testene. 
Inhalasjonspreparater av cortison (Pulmicort®, Flutide®, Aerobec®, Becotide® m.m.) skal ikke 
brukes undersøkelsesdagene før testene. 
Teophylline preparater (TheoDur®,  Nuelin deport®) skal ikke brukes de siste 3 døgn før testene. 
Atrovent® skal ikke brukes de siste 12 timer før testene. 
Lomudal til inahlasjon skal ikke brukes de siste 8 timer før testene. 
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Hvorfor vi gjør denne studien: 
En tredemølletest blir vanligvis utført med en intensitet som er beregnet ut i fra estimert maksimal 
hjertefrekvens. Det har blitt hevdet at intensiteten som oppnås ved en slik tilnærming ikke 
nødvendigvis er tilstrekkelig for å utløse sammentrekning av luftrørene (bronkiene). En repetert test, 
basert på kunnskap fra den første testen, kan gjøre det mulig å justere intensiteten mer individuelt. I 
tillegg har vi en hypotese, basert på klinisk erfaring, om at pasienter som gjennomfører en 
tredemølletest for andre gang utfører testen med en høyere intensitet da de er mer vant til testen og 
tredemølla. Hovedhensikten med prosjektet er å undersøke effekten av å gjennomføre en repetert 
tredemølletest for å diagnostisere anstrengelsesutløst astma. Ny kunnskap kan bidra til å tilby 
pasienter mer presise prosedyrer for å diagnostisere anstrengelsesutløst astma.  
 
Mulige fordeler og ulemper: 
Som deltaker har du mulighet til å bidra til ny og etterspurt kunnskap om diagnostisering av 
anstrengelsesutløst astma. Deltagelse i prosjektet medfører en grundig undersøkelse av 
lungefunksjon og ømfintlighet i luftveiene, som videre vil kunne benyttes som grunnlag for 
medisinsk behandling, og for å søke om tillatelse fra det internasjonale dopingbyrået, World 
Antidoping Agency (WADA) om å benytte astmamedisiner i forbindelse med idrett, dersom dette er 
aktuelt. For deltakere i prosjektet dekker klinikken (KAL) utgiftene ved de to testdagene, med 
unntak av reiseutgifter. Dersom du ikke ønsker å delta i studien, vil tester bli utført på vanlig måte. 
Under begge testdagene stilles strenge krav i forhold til deltakeres sikkerhet og studien er dekket av 
Norsk pasientskadeerstatning. Tredemølletesten kan gi astmasymptomer og kan oppfattes som 
ubehagelig. Behandling for eventuelt pustebesvær under eller etter tredemølletesten vil kunne gis 
umiddelbart. De øvrige testene medfører svært liten eller ingen risiko.  
 
Hva skjer med testene og informasjonen om deg: 
Dine resultater fra undersøkelsene formidles direkte til deg under legekonsultasjonen. I tillegg 
samles resultatene i flere forskningsrapporter. Alle opplysningene og testene vil bli behandlet uten 
navn og fødselsnummer eller andre direkte gjenkjennende opplysninger. En kode knytter deg til dine 
opplysninger og prøver, gjennom en navneliste. Det er kun autorisert personell knyttet til prosjektet 
som har adgang til navnelisten og som kan finne tilbake til deg. Det vil ikke være mulig å 
identifisere deg i resultatene av studien når disse publiseres. 
 
Personvern og frivillig deltakelse: 
Det er frivillig å delta i studien og du kan når som helst og uten å oppgi grunn trekke ditt samtykke. 
Dette vil ikke få konsekvenser for din videre behandling, eller forholdet til klinikken (KAL). Dersom 
du trekker deg fra studien har du rett til innsyn i data registrert om deg. Du kan kreve å få slettet 
innsamlede prøver og opplysninger, med mindre opplysningene allerede er inngått i analyser eller 
brukt i vitenskapelige publikasjoner. Dersom du ønsker å delta, undertegner du samtykkeerklæringen 
på siste side. Har du spørsmål kan du kontakte ansvarlig lege Thor Arne Grønnerød. 
Personopplysninger og data vil bli oppbevart til utgangen av 2021 og deretter slettet. 
 
Vennlig hilsen forskningsgruppen: 
Thor Arne Grønnerød, Ansvarlig lege, Klinikk for allergi og luftveissykdommer 
Email: tagroenn@online.no,  Tlf: 91854024 
 
Liv Berit Augestad, prosjektleder, professor, NTNU 
Email: Liv.Berit.Augestad@SVT.NTNU.NO, Tlf: 90290434   
 
Trine Stensrud, Prosjektmedarbeider, 1. amanuensis, NiH 
Email: Trine.Stensrud@nih.no, Tlf: 23262346 
 
Maj Røsvik Angell, Prosjektmedarbeider, Masterstudent, NTNU 
Email:majangell@gmail.com, Tlf: 91338088  
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Samtykke til deltakelse i forskningsprosjektet  
For deltakeren: 
Jeg har lest informasjonsskrivet om å delta i forskningsprosjektet:  
”Sammenligning av to tredemølletester (provokasjonstester) for vurdering av 
anstrengelsesutløst astma” og gir mitt samtykke til deltagelse i prosjektet. Jeg er kjent med 
at jeg når som helst kan trekke meg fra prosjektet uten å måtte oppgi grunn for det. Jeg er 
klar over at de innsamlede data utelukkende brukes til forskning.  
 
Jeg samtykker i å delta i prosjektet som innebærer følgende:  
 
• Utfylling av spørreskjema  
• Måling av blodtrykk og hvile EKG 
• Målinger av utåndet nitrogenoksid 
• Målinger av lungefunksjon før og etter tredemølletester 
• Målinger av maksimal frivillig ventilasjon 
• Tredemølletester med registrering av oksygenopptak og puls 
• Målinger av lungevolum og luftveismotstand 
• Målinger av diffusjonskapasitet 
 
 
 
 
------------------------------------------------------------------------------------------------------------- 
(Deltakers fulle navn, bruk BLOKKBOKSTAVER)  
 
 
Dato:    Signatur: 
-------------------------------------------------------------------------------------------------------------- 
 
 
 
 
På dagtid kan jeg kontaktes på telefonnummer: 
 
--------------------------------------------------------------------------------------------------------------- 
Samtykket returneres til Klinikk for allergi og luftveissykdommer (KAL) i 
den ferdig adresserte konvolutten. Porto er betalt.  
 
 
 
 
 
 
 
Utfylles av klinikken (KAL): 
Herved bekreftes at informasjon om studien er gitt 
 
---------------------------------------------------------------------------------------------------------------- 
(Signatur, rolle i studien, dato) 
 
 
Til:
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